
Isomorphic raises $5B in the largest biotech venture round yet. AI drug design company’s series C round comes just six months after a $2.1B round, and before a program has entered the clinic. buff.ly/Tw7bj66

The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis: bit.ly/4b1HDDu

Isomorphic raises $5B in the largest biotech venture round yet. AI drug design company’s series C round comes just six months after a $2.1B round, and before a program has entered the clinic. buff.ly/Tw7bj66

Biopharmas should invest in tools to close biological AI’s data gaps — a Perspective by BioCentury's Lindsay Martin. Shared initiatives can set the foundation, but biopharmas should invest in measurements that address gaps relevant to their portfolios buff.ly/Rc9YTRM

On the latest #BioCenturyThisWeek podcast: J&J’s $2B NewCo buy, neoantigen vaccines, Overton odds $JNJ $MRK $MRNA buff.ly/DBKJyq3

FDA held Summit to its survival bar for ivonescimab in EGFR-mutant lung cancer. The pivotal trial met its PFS endpoint but missed on overall survival. Longer follow-up showed a similar survival trend favoring ivonescimab in Western and Asian patients. buff.ly/264hJ3j

In BioCentury's Deals Report: Lilly acquires stealthy oncology play Calytrix; plus J&J/Ollin, Vor/RemeGen, BioNTech/Scholar Rock, and more buff.ly/IisknQH

J&J is buying Ollin Bio, a privately held developer of a treatment for ophthalmic disorders that could compete with Roche's Vabysmo, for $2.2B up front buff.ly/6H8FIY7

Sofinnova Partners goes bigger with €725M Crossover II fund to support European companies for longer buff.ly/tAvCVIu

BIO’s plan for ‘securing America’s biotech century’: Trade group trying to use China as a fulcrum to advance policies to enhance U.S. competitiveness buff.ly/3S8Fwes

China’s innovation moment sees a rise in first in class: BioCentury's Simone Fishburn & Lindsay Martin's scene setter analysis for BioCentury-BayHelix China Healthcare Summit 2026 buff.ly/3Mmv7E2

EMA’s CHMP backs new medicines from Hansoh, Innovent, AstraZeneca. Two out of three new drugs recommended at Committee’s November meeting are from Chinese originators. buff.ly/Ad04wjr

In BioCentury's Finance Report: Windward rises 68% after pricing IPO; Rezera's listing stalls; PepGen's offering follows DM1 data; venture rounds for Neurosterix, Delix; and more buff.ly/iQq1lXy

TMC’s William McKeon on making Texas the U.S. pilot for faster trials. @TXMedCenter CEO in conversation with BioCentury's @FishburnSimone buff.ly/kE0AYzW

A year after Pfizer paid $10B to acquire Metsera and its metabolic programs, the pharma is now turning to Blackstone for cash to support a late-stage molecule for obesity buff.ly/z1zCjaD

At #SITC26, logic-gated CAR Ts gained early proof of concept and expanded into innovative constructs buff.ly/xIyhsYp

In BioCentury's Management Tracks: FDA's top attorney is resigning; Novo Nordisk introduced a new CFO; Haisco's head of business development is leaving; and more buff.ly/Va4C6uB

Skape Bio: Designing miniproteins for GPCR pockets antibodies struggle to reach. Baker lab spinout combines de novo design with screening in human cells to develop GPCR agonists and antagonists buff.ly/zLR3oE3